First Wave BioPharma, Inc.

The momentum for this stock is not very good. First Wave BioPharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in First Wave BioPharma, Inc..

News

First Wave BioPharma Changes Name to Entero Therapeutics

Globe Newswire Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is ENTO effective May 17, 2024...\n more…

First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market

Globe Newswire BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing in...\n more…

First Wave BioPharma partners with Celiac Journey for Nasdaq event

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month

Globe Newswire BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing in...\n more…

First Wave BioPharma announces publication of research on celiac disease

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

Globe Newswire Paper highlights findings on impact of a gluten-containing diet on serologic status in celiac diseaseBOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI...\n more…